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Purpose: The aim of this study was to evaluate the
safety, tolerability, and pharmacokinetic parameters
of up to 15 dose levels of ONO-4232, a selective
agonist for the EP4 subtype of the prostaglandin E2
receptor, with a dual left ventricular lusitropic and
venodilatory action, in healthy, adult, male and female
volunteers.
Methods: In this randomized, single-center, double-
blind, placebo-controlled, single-dose, sequential-
group escalation, ﬁrst in human study, ONO-4232
(0.001, 0.003, 0.01, 0.02, 0.04, 0.08, 0.12, 0.15,
0.18, or 0.27 ng/kg/min) or placebo was administered
as a continuous intravenous infusion over 3 hours.
Safety, tolerability, and pharmacokinetic data were
collected during dosing and over a period of 3 days
(Day –1 to Day 2), and at the follow-up visit (Day 7
[2 days]).
Findings: Fifty-seven subjects received ONO-4232
and 19 subjects received placebo. Ten of the planned
15 cohorts (dose range, 0.001–0.27 ng/kg/min) were
conducted. A total of 34 treatment-emergent adverse
events (TEAEs) were reported in 23 subjects. Overall,
the majority of TEAEs were mild. No serious TEAEs
or deaths were reported and no subjects discontinued
due to adverse events. The most frequently reported
TEAE was infusion site erythema. A decrease in
systolic blood pressure from baseline occurred for
ONO-4232 subjects compared with placebo that was
statistically signiﬁcant for the 0.08 ng/kg/min dose,
and a dose-dependent increase in heart rate starting at
0.04 ng/kg/min and achieving statistical signiﬁcanceMay 2016compared with placebo at 0.15 ng/kg/min and above.
More orthostatic events occurred in the higher-dose
groups and the dose escalation was terminated due to
increasing occurrences of orthostatic hypotension/in-
tolerance. Plasma concentrations of ONO-4232
reached steady state approximately 2 hours after the
start of infusion and then declined rapidly after the
end of infusion, and systemic exposure appeared to
increase in a dose-proportional manner. Approxi-
mately 30% of the administered dose of ONO-4232
was excreted in the urine.
Implications: In healthy adults ONO-4232 was
generally well tolerated in the dose range of 0.001 to
0.27 ng/kg/min. There were dose-related changes in
systolic blood pressure and heart rate. Infusion site
erythema, which was likely associated with a veno-
dilatory effect and possible evidence for the pharma-
cologic effects of ONO-4232, occurred increasingly
with increasing dose. Pharmacokinetic parameters
appeared to be dose-proportional. The study results
support further evaluation of the cardiova-
scular effects of this ﬁrst-in-class selective left ven-
tricular lusitropic and venodilatory drug in
patients with acutely decompensated heart failure.1109
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Heart failure (HF) is a complex clinical syndrome that
results from any structural or functional impairment
of ventricular ﬁlling or ejection of blood leading to
failure of the heart to deliver oxygen at a rate
commensurate with the requirements of the metabo-
lizing tissues. The cardinal symptoms of HF are
dyspnea, fatigue, and ankle swelling, and the signs
are elevated jugular venous pressure, pulmonary
crackles, and displaced apex beat.1,2 Renal impair-
ment is common in HF and is associated with adverse
outcomes in patients with acute HF.3
Despite major improvements in the treatment of
virtually all cardiac disorders, HF is an exception
because prevalence is rising and only small prolonga-
tions in survival are occurring.4–6 In 2010, more than
41 million patients were living with HF globally7 and
hospitalizations for HF in the United States tripled
between 1979 and 2004.5 Hospitalizations and
subsequent readmissions place a considerable burden
on patients, health care providers, and the health care
system. Despite modest improvement in survival after a
diagnosis of HF and increase of mean age at death
from HF, in patients hospitalized for HF the mortality
at 60 to 90 days is 15%, the mortality at 1 year reaches
30% and the 5-year mortality is 60% to 65%, which is
comparable to, or worse than, that of many cancers.8,9
Worsening renal function in patients with acute HF
correlates with greater mortality, length of stay, and
readmission rates for HF.10 There is a major unmet
need to develop additional treatments for hospitalized
HF patients that will provide relief of symptoms of
decompensated cardiovascular congestion, improve
cardiac and renal functions and outputs, and reduce
mortality and morbidity.
ONO-4232 is a novel, ﬁrst-in-class, small molecule,
selective agonist for the EP4 subtype of the prosta-
glandin E2 receptor. EP4 is known to be distributed in
many tissues, including blood vessels, and effects
include vasodilation, increased renal blood ﬂow
(ONO data, not presented), angiogenesis, protection
from cardiac ischemia/reperfusion injury, inhibition of1110platelet aggregation, and suppression of inﬂammatory
cells and cytokines such as tumor necrosis factor-α.11–17
EP4 is selectively distributed to smooth muscle cells in
human pulmonary veins and therefore EP4 agonists
would be expected to dilate the pulmonary vein and not
the pulmonary artery.18
ONO-4232 has demonstrated improvement of
Calcium (Ca2þ) handling in failing canine cardiomyo-
cytes19 and has been investigated in models of canine
acute HF and rat chronic HF.20 In a canine acute HF
model, intravenous ONO-4232 signiﬁcantly improved
central and peripheral hemodynamic (HD) parameters
as well as improving urine output and blood oxygen
saturation.20 HD effects included selective left ventricle
(LV) relaxation and venous vasodilation in addition to
the dose-related reduction in blood pressure.20 In a rat
chronic HF model, a chronic oral ONO-4232 treatment
improved LV diastolic and systolic dysfunction and
prevented cardiac ﬁbrosis.20 An additive effect in
combination with the angiotensin II receptor blocker
candesartan demonstrated improvements in survival.20
In addition, intravenous ONO-4232 showed a signiﬁ-
cant LV relaxation and reduction in pulmonary capillary
wedge pressure (PCWP) in a canine chronic HF model.21
ONO-4232 demonstrated preservation of partial pres-
sure of oxygen (PaO2) under conditions of induced
partial pulmonary hypoxia in canines, suggesting that it
does not increase pulmonary shunting,22 unlike other
vasodilators such as epoprostenol and nitroglycerin.22–24
Following intravenous infusion of ONO-4232 to rats
and dogs, the exposure of ONO4232 increased propor-
tionally with dose; plasma ONO-4232 concentrations
declined rapidly with t½ in the range of 0.50 to 1.4 hours
in rats and 0.26 hours in dogs (Ono internal data).
At present, a ﬁrst-in-human Phase I study in
healthy men and women has been completed and
the results are presented. ONO-4232 is being devel-
oped by ONO Pharmaceutical Co, Ltd, Osaka, Japan,
for the treatment of patients with acutely decompen-
sated heart failure and it is anticipated that ONO-
4232 may address both cardiac and renal aspects of
this syndrome.SUBJECTS, STUDY DESIGN, AND METHODS
Subjects
All subjects were healthy (as determined by the
investigator) men or women aged 18 to 55 years
(inclusive) with systolic blood pressure (SBP)Volume 38 Number 5
C.L. Ward et al.4110 mm Hg and heart rate (HR) 450 beats/min at
screening and a normal standard 12-lead ECG. Sub-
jects had to have a body mass index of 19 to 35.
Subjects with a history of clinically signiﬁcant cardi-
ovascular disorders were excluded.
Study Design and Objectives
This was a ﬁrst-in-human, single-center, random-
ized, double-blind, placebo-controlled dose escalation
study conducted by Pharmaceutical Product Develop-
ment (PPD), Inc., Phase 1 Unit, Austin, TX, USA
between October 2013 and February 2014. The
protocol and associated documents were approved
by IntegReview Ethical Review Board. The study was
performed in compliance with the ethical principles
founded in the Declaration of Helsinki, the Interna-
tional Conference on Harmonisation harmonized
tripartite guideline regarding Good Clinical Practice,
US federal regulatory requirements, and local laws
and regulations. Before screening, all study partici-
pants read and signed the informed consent form.
Each subject was free to withdraw from the study at
any time. Although the Consolidated Standards of
Reporting Trials statement recommends registration
of clinical trials in trial registry, this trial was con-
ducted in the United States under an Investigational
New Drug application and, according to FDAAA 801
(Section 801 of the Food and Drug Administration
Amendments Act), Phase I drug trials are not required
to be registered. Therefore this trial was not registered.
Healthy male and female subjects were randomized
to receive a 3-hour intravenous infusion of ONO-
4232 or placebo (0.9% normal saline) in the ratio 3:1
with 4 subjects dosed in the ﬁrst cohort and 8 in
subsequent cohorts. The randomization list was gen-
erated using an arbitrary seed by PPD staff not
involved in the conduct of the study. The study
comprised 3 periods as follows: screening period of
up to 27 days (Day –28 to Day –2) to qualify subjects
for the study, dosing and evaluation period of 3 days
(Day –1 to Day 2) during which subjects remained
in a clinical unit, and a follow-up visit on Day 7
(2 days). The duration of the study for each subject
was between 7 and 9 days and each subject only
participated in 1 cohort.
Study medication was administered over a single
3-hour period as a continuous intravenous infusion at
a constant rate of 10 mL/h, total infusion volume
30 mL, using an infusion pump. Up to 15 cohortsMay 2016were planned in a single escalating dose design to
explore up to 15 doses of ONO-4232: 0.001, 0.003,
0.01, 0.02, 0.04, 0.08, 0.12, 0.18, 0.27, 0.405, 0.607,
0.911, 1.36, 2.05, and 3.075 ng/kg/min. The starting
dose was approximately 50-fold below the minimum
anticipated biological effect level that decreased blood
pressure in anesthetized dogs (data not shown) and
the incremental dose increase was considered appro-
priate for safety and tolerability assessment. The
protocol allowed for adjustment of doses based on
emerging safety, tolerability, pharmacokinetic (PK)
parameters, and HD effects. No food was allowed
from 10 hours before dosing to at least 2 hours after
the end of the 3-hour infusion. Water was permitted
ad libitum before the infusion but was limited during
the infusion.
The primary objective was to evaluate the safety
and tolerability of ONO-4232. Secondary objectives
were to characterize the PK proﬁle by measuring
plasma and urine concentrations of ONO-4232 and
to evaluate the effects of ONO-4232 on blood
pressure and HR.
Safety and Tolerability
Subjects were monitored for adverse events (AEs)
during the dosing and evaluation period through to
follow-up (coded using Medical Dictionary for Drug
Regulatory Affairs version 16.1). Subjects were
monitored for concomitant medications from screen-
ing period to the follow-up visit. In addition, safety
and tolerability were assessed through complete or
brief physical examinations at screening, Day –1,
predose, end of infusion (EOI), 1 and 24 hours post-
EOI, and follow-up. Observations of body weight
were made at screening, Day –1, 24 hours post-EOI,
and at follow-up. Twelve-lead ECG, including all
timing interval duration measurements, was con-
ducted at screening, predose, at 1 and 3 hours, at
1 and 24 hours post-EOI, and at follow-up. Cardiac
telemetry was continuous from Day –1 to 24 hours
post-EOI. Safety laboratory evaluations were con-
ducted at screening, Day –1, and 3 hours, and 6 and
24 hours post-EOI and at follow-up. Vital signs
assessment included HR and blood pressure, which
were measured in the semisupine position at screen-
ing, Day –1, predose, and 15 and 30 minutes as well
as 1, 2, and 3 hours during the infusion as well as 5,
15, and 30 minutes, 1 and 24 hours after the EOI,
and at follow-up. An orthostatic test was conducted1111
Clinical Therapeutics5 and 60 minutes after the EOI comprising measure-
ment of seated and standing blood pressure. In the
case that subjects experienced orthostatic hypoten-
sion, the readings were repeated after the subject had
been supine for 10 minutes. Orthostatic hypotension
was deﬁned as a decrease in SBP of 20 mm Hg within
3 minutes of standing when compared with respec-
tive blood pressure values from the sitting or supine
position; orthostatic intolerance was deﬁned as the
development of symptoms (eg, feeling lightheaded or
dizzy, fainting or near-fainting syncope, weakness,
confusion, nausea, and blurry vision) that stopped
seated and/or standing blood pressure measurements
being performed due to a need to resume a supine
position. The protocol contained stopping rules
based on the absolute and relative changes in blood
pressure and HR from baseline to ensure subjects’
safety.
PK
Blood samples were taken by venipuncture for
analysis of plasma levels of ONO-4232. Sampling
was at predose and during the 3-hour infusion at 15
and 30 minutes, 1, 2, and 3 hours, and also post-
infusion at 5, 10, 15, and 30 minutes and 1, 2, 4, 6,
and 24 hours. In addition, urine samples were col-
lected at predose (spot urine) and pooled from 0 to 12
and 12 to 27 hours from the start of the infusion.
Plasma and urine concentrations of ONO-4232 were
determined using validated HPLC-MS/MS methods
with quantitative range of 1 to 100 pg/mL and 5 to
1000 pg/mL, respectively. Liquid-liquid extraction
was used to extract ONO-4232 from plasma and
urine constituents. The organic layer was separated
and evaporated. The residue was reconstituted. The
resulting samples were injected into the HPLC-MS/MS
system.
Plasma and urine PK parameters were calculated
using SAS version 9.2 (SAS Institute, Cary, North
Carolina) and Phoenix WinNonlin version 6.2.1
(Certara, St Louis, Missouri) using a standard non-
compartmental model. Where concentrations allowed,
the following PK parameters were calculated for
ONO-4232: area under the concentration versus time
curve from time 0 to the last sampling time point
(AUClast), area under the concentration versus time
curve from time 0 extrapolated to inﬁnity (AUC1),
concentration at the end of infusion (Ceoi), maximum
observed concentration (Cmax), total clearance (CL),1112elimination half-life (t1/2), time to reach Cmax (Tmax),
volume of distribution at steady state (Vss), volume of
distribution based on the terminal phase (Vz), and
fraction of dose excreted unchanged in urine (fe).
Statistical Considerations
No a priori statistical assumptions were made for
sample size, which was based on including sufﬁcient
subjects to assess PK and safety while minimizing the
risk to patients in early drug development. The safety
set comprised all subjects enrolled in the study who
were exposed to study medication; this was used for
all analyses. The PK analysis population included all
enrolled subjects who received ONO-4232 and had at
least 1 postdose PK sample taken.
Statistical analyses were conducted using SAS
version 9.4. The exploratory analysis of vital signs
data was a post hoc analysis conducted to evaluate the
changes in blood pressure and HR when compared
with placebo data. To permit exploration of the time-
course of changes from baseline in vital signs and to
account for the correlation in the repeated measures
within subject, changes from baseline (CFB) in HR
were compared with CFB for placebo using a mixed-
effect model with repeated measures with baseline HR
as a covariate. CFB in blood pressure were compared
with CFB for placebo using a similar mixed-effect
model with repeated measures that included baseline
blood pressure as a covariate. No imputation was
made for missing data.
Plasma and urine PK parameters were analyzed
using SAS version 9.2. Summary statistics were calcu-
lated for all PK parameters by dose level. Dose
proportionality of Cmax and AUC1 was evaluated
by a power model. The point estimate of the intercept
and slope (β) with 95% CI was calculated by linear
regression according to the least squares method.
Doses that did not result in calculable PK parameters
were not tested.RESULTS
Disposition and Demographic Characteristics
Seventy-six subjects were randomized; a total of
57 subjects received a single 3-hour infusion of ONO-
4232 and 19 subjects received placebo. Baseline
characteristics are shown in Table I. All subjects
received their planned dose of study medication and
all subjects completed the infusion. Of the planned 15Volume 38 Number 5
Table I. Baseline characteristics of healthy volunteers by dose group.
ONO-4232, ng/kg/min
Total Placebo 0.001 0.003 0.01 0.02 0.04 0.08 0.12 0.15 0.18 0.27
(n ¼ 76) (n ¼ 19) (n ¼ 3) (n ¼ 6) (n ¼ 6) (n ¼ 6) (n ¼ 6) (n ¼ 6) (n ¼ 6) (n ¼ 6) (n ¼ 6) (n ¼ 6)
Age, y Mean 34.6 (19–55) 36.4 (22-53) 30.7 (29–33) 33.5 (27-44) 36.2 (20–55) 35.2 (24–41) 31.8 (21–45) 31.5 (24–42) 33.5 (19–52) 37.0 (24–54) 31.5 (20–49) 37.5 (26–49)
Sex,
n (%)
Male 59 (77.6) 13 (68.4) 2 (66.7) 6 (100.0) 5 (83.3) 5 (83.3) 5 (83.3) 5 (83.3) 4 (66.7) 5 (83.3) 5 (83.3) 4 (66.7)
Female 17 (22.4) 6 (31.6) 1 (33.3) 0 1 (16.7) 1 (16.7) 1 (16.7) 1 (16.7) 2 (33.3) 1 (16.7) 1 (16.7) 2 (33.3)
Race,
n (%)
White 59 (77.6) 15 (78.9) 3 (10.0) 6 (100) 4 (66.7) 5 (83.3) 4 (66.7) 4 (66.7) 5 (83.3) 5 (83.3) 5 (83.3) 3 (50.0)
Black or African
American
13 (17.1) 4 (21.1) 0 0 1 (16.7) 1 (16.7) 1 (16.7) 1 (16.7) 1 (16.7) 0 1 (16.7) 3 (50.0)
Native Hawaiian
or other
Paciﬁc
Islander
1 (1.3) 0 0 0 0 0 1 (16.7) 0 0 0 0 0
Asian 3 (3.9) 0 0 0 1 (16.7) 0 0 1 (16.7) 0 1 (16.7) 0 0
Ethnicity,
n (%)
Hispanic or
Latino
32 (42.1) 10 (52.6) 1 (33.3) 5 (83.3) 1 (16.7) 4 (66.7) 3 (50.0) 2 (33.3) 2 (33.3) 1 (16.7) 2 (33.3) 1 (16.7)
Not Hispanic
or Latino
44 (57.9) 9 (47.4) 2 (66.7) 1 (16.7) 5 (83.3) 2 (33.3) 3 (50.0) 4 (66.7) 4 (66.7) 5 (83.3) 4 (66.7) 5 (83.3)
Body mass
index
Mean 27.00 28.32 27.33 26.43 27.85 28.20 27.95 24.62 24.23 26.85 26.72 25.83
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Table II. Adverse events by system organ class, frequency, and relatedness.
ONO-4232, ng/kg/min Placebo
System Organ Class
0.001
(n ¼ 3)
0.003
(n ¼ 6)
0.01
(n ¼ 6)
0.02
(n ¼ 6)
0.04
(n ¼ 6)
0.08
(n ¼ 6)
0.12
(n ¼ 6)
0.15
(n ¼ 6)
0.18
(n ¼ 6)
0.27
(n ¼ 6) (n ¼ 19)
n (%)
Subjects with treatment-
emergent
adverse event*
0 1 (16.7) 0 2 (33.3) 0 4 (66.7) 1 (16.7) 3 (50.0) 4 (66.7) 5 (83.3) 3 (15.8)
General disorders and
administration
site conditions
0 0 0 1 (16.7) 0 2 (33.3) 1 (16.7) 1 (16.7) 3 (50.0) 3 (50.0) 0
Infusion site erythema 0 0 0 0 0 2 (33.3)† 1 (16.7)† 1 (16.7)† 3 (50.0)† 2 (33.3)† 0
Application site dermatitis 0 0 0 1 (16.7) 0 0 0 0 0 0 0
Fatigue 0 0 0 0 0 0 0 0 0 1 (16.7) 0
Feeling hot 0 0 0 0 0 0 0 0 1 (16.7)† 0 0
Nervous system disorders 0 0 0 0 0 1 (16.7) 0 0 2 (33.3) 2 (33.3) 2 (10.5)
Headache 0 0 0 0 0 0 0 0 0 2 (33.3)† 1 (5.3)
Presyncope 0 0 0 0 0 1 (16.7) 0 0 1 (16.7) 0 1 (5.3)
Dizziness 0 0 0 0 0 0 0 0 1 (16.7)† 0 0
Orthostatic intolerance 0 0 0 0 0 0 0 0 0 1 (16.7)†,‡ 0
Vascular disorders 0 0 0 0 0 1 (16.7) 0 1 (16.7) 0 2 (33.3) 0
Orthostatic hypotension 0 0 0 0 0 1 (16.7)† 0 1 (16.7)‡,† 0 2 (33.3)†,‡ 0
Musculoskeletal and connective
tissue disorders
0 0 0 0 0 0 1 (16.7) 1 (16.7) 0 0 1 (5.3)
Musculoskeletal chest pain 0 0 0 0 0 0 0 1 (16.7) 0 0 1 (5.3)
Myalgia 0 0 0 0 0 0 1 (16.7)† 0 0 0 0
Gastrointestinal disorders 0 0 0 0 0 0 0 0 1 (16.7) 1 (16.7) 0
Diarrhea 0 0 0 0 0 0 0 0 0 1 (16.7)† 0
Nausea 0 0 0 0 0 0 0 0 1 (16.7)†,‡ 0 0
Vomiting 0 0 0 0 0 0 0 0 1 (16.7)†,‡ 0 0
Infections and infestations 0 0 0 1 (16.7) 0 1 (16.7) 0 0 0 0 0
Inﬂuenza 0 0 0 1 (16.7) 0 0 0 0 0 0 0
Nasopharyngitis 0 0 0 0 0 1 (16.7) 0 0 0 0 0
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Figure 1. Change from baseline in heart rate and
blood pressure compared with placebo
during a 3-hour infusion period by
treatment group plotted as mean
(SE) for (A) systolic blood pressure
(SBP), (B) diastolic blood pressure
(DBP), and (C) heart rate (HR).
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May 2016cohorts, 10 cohorts were conducted, evaluating 0.001,
0.003, 0.01, 0.02, 0.04, 0.08, 0.12, 0.15, 0.18, and
0.27 ng/kg/min doses of ONO-4232; the dose
escalation was slightly altered from the planned
schedule based on emerging safety data.Safety and Tolerability
A total of 34 treatment-emergent AEs (TEAEs)
were reported in 23 subjects. Overall, the majority
of TEAEs were mild. No serious TEAEs or deaths1115
Clinical Therapeuticswere reported and no subjects discontinued due to
AEs. More events were reported at the higher doses of
ONO-4232, by subjects who received 0.18 or 0.27 ng/
kg/min ONO-4232, and more of the events reported
at these higher doses were considered related to study
treatment by the investigator (Table II). Following
treatment with ONO-4232, the most frequently reported
TEAE was infusion site erythema (self-limited vein
redness tracking to the site of infusion and not
associated with other symptoms). This event was
reported by at least 1 subject in each cohort who
received ONO-4232 at a dose of 0.08 ng/kg/min or
higher. Other TEAEs reported by 41 subject in any
cohort were headache and orthostatic hypotension (each
reported by 2 subjects who received 0.27 ng/kg/min
ONO-4232). None of the subjects met the safety criteria
for stopping doses. No AEs were considered related to
study treatment by the investigator in subjects who
received 0.001, 0.003, 0.01, 0.02, and 0.04 ng/kg/min
ONO-4232. Three subjects who received placebo re-
ported AEs. These were headache (1 subject), presyncope
(1 subject), and musculoskeletal chest pain (1 subject); all
were considered unrelated to study drug.
More orthostatic events, either orthostatic hypotension
or orthostatic intolerance, occurred in the higher-dose
groups (Table II). There were isolated incidences of
orthostatic hypotension in some subjects post-EOI,
although the mean value for maximum decrease in SBP
was similar across the dose groups. A trend was noted
regarding the ONO-4232 induced decrease from baseline
in both diastolic blood pressure (DBP) and SBP and
increase from baseline in HR (Figure 1). From 0.15 ng/kg/
min and above and for all ONO-4232 dose levels
combined, a greater increase from baseline in HR versus
placebo was conﬁrmed by the post hoc analysis (P o
0.05). From 0.08 ng/kg/min, greater decreases from
baseline in blood pressure compared with placebo were
evident for DBP and particularly for SBP; however, due to
high variability only 0.08 ng/kg/min dose achieved
statistical signiﬁcance (P o 0.05). In some subjects, the
reduction in SBP was associated with increase in HR.
There were no clinically signiﬁcant 12-lead ECG or
telemetry abnormalities and no evidence of a dose-
related trend in changes in QTc (corrected with either
Bazett's or Fridericia’s formulae) over time.
There were no clinically signiﬁcant abnormal clinical
laboratory values during the study, except a transient
increase in blood creatinine phosphokinase level in a
52-year-old white female subject who received 0.121116ng/kg/min ONO-4232 and also experienced transient
mild myalgia in her biceps. The event was considered
possibly related to study treatment by the investigator.
PK
PK parameters were not calculated for the 0.001 or
0.01 ng/kg/min dose group because concentrations
were below the limit of quantiﬁcation. Partial PK
parameters were calculated for the 0.003 and 0.02
ng/kg/min dose groups because some samples had
measureable concentrations of ONO-4232 (Table III).
The plasma concentration of ONO-4232 reached
steady state after approximately 2 hours and the
median Tmax for all cohorts with measurable plasma
concentrations was approximately 3 hours. Plasma
ONO-4232 concentrations declined rapidly with
mean t1/2 of 0.26 to 0.64 hours for doses ranging
from 0.04 to 0.27 ng/kg/min (Figure 2). Across the
same dose range, mean total clearance and volume of
distribution based on the terminal phase ranged from
54.2 to 81.1 L/h and from 23.0 to 57.6 L, respectively
(Table III). Dose proportionality was observed for
Cmax from 0.02 to 0.27 ng/kg/min with the point
estimates (95% CI) of β of 0.96 (0.90–1.03) and
for AUC1 from 0.04 to 0.27 ng/kg/min with the
point estimates (95% CI) of β of 0.97 (0.87–1.08)
(Table IV).
Excretion of ONO-4232 in urine was essentially
completed by 12 hours following the start of infusion
at all quantiﬁed dose levels, with little quantiﬁable
drug present in the urine between 12 and 27 hours.
The total fraction excreted unchanged ranged from
29.4% to 36.3%. The PK data for ONO-4232 in
urine are depicted in Table V.DISCUSSION
ONO-4232 is a novel, ﬁrst-in-class, selective agonist
for the EP4 subtype of the prostaglandin E2 receptor
with a dual LV-lusitropic and venodilatory action
which preserves PaO2 in preclinical models that are
being developed for the treatment of patients with
acutely decompensated heart failure. Due to the early
stage of development of ONO-4232, the structure is
not available for publication.
ONO-4232 was safe and generally well tolerated.
The most frequent AE of erythema tracking to the site
of infusion seen increasingly with escalating doses
could be described as a dose-related redness in theVolume 38 Number 5
Table III. Pharmacokinetic parameters for ONO-4232 in plasma.
Parameter, mean (SD)
ONO-4232
0.001 ng/kg/min
(n ¼ 3)
ONO-4232
0.003 ng/kg/min
(n ¼ 6)
ONO-4232
0.01 ng/kg/min
(n ¼ 6)
ONO-4232
0.02 ng/kg/min
(n ¼ 6)
AUC1, pg  h/mL NC NC* NC* NC†
AUClast, pg  h/mL NC 0.463 (NC) NC 3.59 (0.360)
Clearance, L/h NC† NC† NC† NC†
Cmax, pg/mL BLQ 0.463 (NC) BLQ 1.60 (0.128)
Ceoi, pg/mL BLQ BLQ BLQ 1.56 (0.108)
t½, h NC
† NC† NC† NC†
Tmax, h
‡ NC† 7.0 (7.0, 7.0)§ NC† 3.0 (3.0, 3.1)
Vss, L NC† NC† NC† NC†
Vz, L NC† NC† NC† NC†
ONO-4232
0.04 ng/kg/min
(n ¼ 6)
ONO-4232
0.08 ng/kg/min
(n ¼ 6)
ONO-4232
0.12 ng/kg/min
(n ¼ 6)
ONO-4232
0.15 ng/kg/min
(n ¼ 6)
AUC1, pg  h/mL 8.95 (0.931)* 17.2 (3.11)* 29.2 (4.80) 29.4 (3.08)
AUClast, pg  h/mL 8.34 (0.862) 16.4 (2.60) 28.2 (4.62) 28.7 (2.94)
Clearance, L/h 67.0 (7.47)* 62.0 (9.68)* 54.2 (10.9) 71.9 (5.95)
Cmax, pg/mL 3.08 (0.295) 6.50 (0.955) 10.4 (1.52) 10.4 (0.876)
Ceoi, pg/mL 3.06 (0.328) 5.70 (0.941) 9.93 (1.81) 10.2 (0.749)
t½, h 0.26 (0.065)
* 0.26 (0.069)* 0.42 (0.064) 0.38 (0.039)
Tmax, h
‡ 3.0 (2.0, 3.0) 3.0 (2.0, 3.1) 3.0 (1.0, 3.1) 3.0 (2.0, 3.1)
Vss, L 29.2 (2.91)* 27.5 (5.16)* 30.6 (9.21) 38.7 (5.99)
Vz, L 24.8 (5.71)* 23.0 (4.78)* 33.2 (9.03) 39.1 (5.61)
ONO-4232
0.18 ng/kg/min
(n ¼ 6)
ONO-4232
0.27 ng/kg/min
(n ¼ 6)
AUC1, pg  h/mL 33.4 (6.47) 63.3 (9.27)
AUClast, pg  h/mL 32.5 (6.21) 61.9 (9.14)
Clearance, L/h 81.1 (6.80) 61.7 (16.3)
Cmax, pg/mL 12.0 (2.73) 21.5 (4.82)
Ceoi, pg/mL 11.6 (2.70) 20.0 (3.11)
t½, h 0.34 (0.088) 0.64 (0.16)
Tmax, h
‡ 3.0 (2.0, 3.1) 3.0 (2.0, 3.1)
Vss, L 40.2 (7.50) 37.1 (13.4)
Vz, L 39.9 (10.6) 57.6 (25.0)
BLQ ¼ below limit of quantiﬁcation; NC ¼ not calculated.
*n ¼ 5.
†n ¼ 0.
‡Median (minimum, maximum) was reported for Tmax.
§n ¼ 1.
C.L. Ward et al.
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Clinical Therapeuticstrack of the vein. This is believed to be due to
vasodilation as a consequence of EP4 agonistic effects
on vasa vasorum. EP4 is known to affect vasodilation
and renal blood ﬂow, making an EP4 agonist a good0 1 2 3 4 5 6
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1118potential treatment for multiple aspects of HF. Pre-
clinical data from models of acute and chronic HF had
previously demonstrated the potent LV-lusitropic and
venous dilating effect of ONO-4232 as well as
improvements in renal blood ﬂow. In addition, a
dose-dependent reduction of SBP was seen in these
models. A trend to a reduction in blood pressure was
seen versus placebo in healthy volunteers as well as
incidents of orthostatic hypotension and orthostatic
intolerance. A post hoc analysis showed the decrease
in blood pressure was not statistically signiﬁcant at all
dose levels, although this was probably due to the high
variability of data and the small number of subjects
studied. This is not unexpected because this study was
designed to evaluate safety and tolerability and was not
powered to detect statistically signiﬁcant changes in
vital signs. The reason for these orthostatic events is
currently unknown and a limitation of this study design
was the absence of a predose orthostatic test to provide
a baseline reading; nevertheless, the increasing inci-
dence of orthostatic events with escalating dose are
related to ONO-4232. Although ONO-4232 improved
urine output in the preclinical acute HF model, in this
study no measurements were made of urine volume,
urine output, or of body weight before and after
infusion to assess changes in renal function, because
in healthy volunteers with an absence of ﬂuid retention
it is unlikely that any beneﬁcial effects on urine output
would be evident.
No pharmacodynamic assessment of central HD
parameters was conducted in this study due to the low
feasibility of detection of direct LV-lusitropic and
venous dilatory signals in healthy individuals withFigure 2. Plasma pharmacokinetics for ONO-4232.
(A) plasma concentration time data
(mean [SD]) for all doses with evaluable
levels of ONO-4232 during and following
a 3-hour infusion of ONO-4232 (0.02
ng/kg/min (○), 0.04 ng/kg/min (), 0.08
ng/kg/min (△), 0.12 ng/kg/min (▲), 0.15
ng/kg/min (▫), 0.18 ng/kg/min (▪), and
0.27 ng/kg/min (X). (B) Cmax dose pro-
portionality data for all doses with evalu-
able levels of ONO-4232; individual data
points are plotted. (C) AUC1 dose pro-
portionality data for all doses with evalu-
able levels of ONO-4232; individual data
points are plotted.
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Table IV. Dose proportionality of pharmacokinetic parameters for ONO-4232.
Dose
Dependent
Variable Intercept
Slope Parameter
Estimate (SE) 95% CI
0.02, 0.04, 0.08, 0.12, 0.15,
0.18, 0.27 ng/kg/min
ln(Cmax) 4.25 0.96 (0.0306) 0.9016–1.0251
ln(AUClast) 5.41 1.04 (0.0305) 0.9812–1.1044
0.04, 0.08, 0.12, 0.15, 0.18,
0.27 ng/kg/min
ln(AUC1) 5.31 0.97 (0.0516) 0.8694–1.0796
C.L. Ward et al.normal hearts and normal diastolic function. Never-
theless, it is reasonable to speculate that ONO-4232
produces a reduction in blood pressure and aug-
mented orthostatic response, particularly, due to its
venodilatory effect. Future studies in patients with HF
would include measurements of peripheral and central
HD parameters. It should be noted that due to the
likely differences in vascular tone in patients with
acutely decompensated heart failure, these data in
healthy volunteers may not necessarily be predictive of
effects in this patient population.
Because ONO-4232 has short t½, steady state is
reached quickly, plasma concentration is proportional
to dose, and declines rapidly after the end of infusion,
suggesting ONO-4232 has a controllable PK proﬁle as
a drug for intravenous infusion.CONCLUSIONS
These data support the further evaluation of the
cardiovascular effects of this ﬁrst-in-class lusitropic
drug in patients with acute HF, a syndrome with aTable V. Mean pharmacokinetic parameters for ONO-4
Parameter, mean (SD)
ONO-4232
0.01 ng/kg/min
(n ¼ 6)
Fraction excreted 0–12 h, % 29.4 (5.39)
Fraction excreted 12–27 h, % NC†
Fraction excreted total, % 29.4 (5.39)
NC ¼ Not calculated.
*Urine concentrations and pharmacokinetic parameters were no
†n ¼ 0.
‡n ¼ 2.
May 2016considerable unmet need. In future studies blood
pressure and HR should be carefully monitored.AUTHOR CONTRIBUTIONS
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